RESUMEN
OBJECTIVE: Augmented reality (AR) and virtual reality (VR) facilitate motor learning by enabling the practice of task-specific activities in a rich environment. Therefore, AR and VR gait training may improve balance and gait in Parkinson's Disease (PD). METHODS: Thirty patients with PD were randomly divided into study (n = 15) and control (n = 15) groups. The study group was given AR and VR gait training combined with conventional training. The control group was given conventional training only. The training was applied to both groups 3 days a week for 6 weeks. Motor symptoms with the Unified Parkinson Disease Rating Scale-Motor Examination (UPDRS-III), balance with posturography and Berg Balance Scale (BBS), perceived balance confidence with Activity-Specific Balance Confidence Scale (ABC), gait with spatio-temporal gait analysis, and functional mobility with Timed Up and Go Test (TUG) were assessed. RESULTS: At the end of the study; UPDRS-III, posturography measurements, BBS, ABC, spatio-temporal gait parameters, and TUG improved in the study group (p < 0.05), while BBS, ABC, and only spatial gait parameters (except for step width) improved in the control group (p < 0.05). There was no change in posturography measurement, temporal gait parameters, and TUG in control group (p > 0.05). When the developed parameters in both groups were compared, the amount of improvement in BBS and ABC was found similar (p > 0.05), while the improvement in the other parameters was found higher in the study group (p < 0.05). CONCLUSION: It was concluded that AR and VR gait training provides the opportunity to practice walking with different tasks in increasingly difficult environments, thus improving balance and walking by facilitating motor learning.
Asunto(s)
Enfermedad de Parkinson , Realidad Virtual , Humanos , Equilibrio Postural , Estudios de Tiempo y Movimiento , Marcha , Terapia por EjercicioRESUMEN
PURPOSE: Although both motor symptoms and non-motor symptoms (NMSs) occur in patients with Parkinson's disease (PD), clinical practice focuses more on motor symptoms. The aim of this study was to examine balance, muscle strength, and mobility in relation with NMSs in patients with PD. The other aim of this study was to investigate the relationship between NMSs and muscle strength, balance, and functional mobility in PD. MATERIALS AND METHODS: The study included 24 patients with PD (between Hoehn & Yahr Stage 1 and 3) and 20 healthy individuals of similar age and sex. The participants' balance was assessed with the Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA), muscle strength assessments were conducted with a Biodex® System 4 Dynamometer device, and functional mobility was assessed with the Timed Up and Go test (TUG). The non-motor symptoms scale was used for NMSs. RESULTS: We found that lower extremity strength scores were lower and NMSs, balance, and mobility scores were greater in patients with PD in comparison to healthy controls (p < 0.05). The correlation analysis revealed that higher NMSs were related to reduced knee extension strength and cognitive dual task performance. CONCLUSION: Although no relationship between NMSs and balance was observed, the relationship between the TUG + cognitive task and muscle strength suggests that NMSs should be carefully evaluated along with the motor symptoms, which deteriorate beginning with the early period.
Asunto(s)
Enfermedad de Parkinson , Humanos , Fuerza Muscular , Enfermedad de Parkinson/complicaciones , Equilibrio Postural , Índice de Severidad de la Enfermedad , Estudios de Tiempo y MovimientoRESUMEN
Background/aim: Levodopa-carbidopa intestinal gel (LCIG) is an effective treatment modality in the management of advanced Parkinson's disease (PD) despite frequent adverse events and different rates of dropouts. Efficacy and safety data regarding Turkish patients on LCIG are limited. This study aims to report in detail the efficacy and adverse effect profile of LCIG among advanced PD patients from a Turkish center for movement disorders. Materials and methods: Twenty-two patients (50% male) who started receiving LCIG between December 2014 and March 2020 were recruited. The efficacy of LCIG was assessed with the Unified Parkinson's Disease Rating Scale (UPDRS III), Clinical Global Improvement (CGI) scale, and Quality of Life scale (PDQ8). Improvements in gait disorders and nonmotor features were also questioned. Adverse events (AE) were collated into 3 topics: related to percutaneous endoscopic gastrojejunostomy (PEG-J), device-related, and LCIG infusion-related. Results: Mean age and pre-LCIG disease duration were 66.7 (8.8) and 13.3 (8.0) years respectively. UPDRS III scores and H-Y scale assessments significantly improved. Better quality of life scores, clinical global improvements, and improvements in dysarthria, dysphagia, and gait were observed. None of our patients dropped out or died during a mean 17.5-month (12.3) period. Overall 20 (90.9%) patients experienced at least one AE. Twelve patients had PEG-Jrelated complications; three had acute abdomen. Eight (36.4%) patients had device-associated problems. Half of the patients required at least one additional endoscopic procedure and 7 had a device replaced. Mean body weight decreased from 69.5 to 62.5 kg and seven patients had newly onset PNP at a follow-up electromyography. Dyskinesia related to LCIG infusion was observed in 5 (22.7%) patients. There was no significant increase in hallucination among patients. Conclusion: LCIG is an efficient treatment modality in the management of Turkish patients with advanced Parkinson's disease. Although most of the patients had at least one AE, none of them dropped out. Patient selection, patient compliance, and collaborative management are important steps affecting the success of modality.
Asunto(s)
Carbidopa/uso terapéutico , Levodopa/uso terapéutico , Enfermedad de Parkinson/tratamiento farmacológico , Índice de Severidad de la Enfermedad , Abdomen Agudo/etiología , Anciano , Carbidopa/administración & dosificación , Carbidopa/efectos adversos , Cateterismo/efectos adversos , Cateterismo/métodos , Trastornos de Deglución/tratamiento farmacológico , Trastornos de Deglución/etiología , Combinación de Medicamentos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Disartria/tratamiento farmacológico , Disartria/etiología , Discinesias/etiología , Endoscopía , Femenino , Marcha , Geles , Humanos , Intestinos , Levodopa/administración & dosificación , Levodopa/efectos adversos , Masculino , Pruebas de Estado Mental y Demencia , Persona de Mediana Edad , Enfermedad de Parkinson/complicaciones , Calidad de Vida , Resultado del Tratamiento , TurquíaRESUMEN
OBJECTIVES: Behçet's syndrome (BS) is a systemic vasculitis, which may involve multiple organ systems simultaneously. Clinical findings in BS often fit into well-recognized patterns, such as the association between papulo-pustular skin lesions and arthritis. We have recently observed a distinct pattern, in which a subtype of neuro-Behçet's syndrome (NBS) is often preceded by specific ophthalmic manifestations of the disease process. The purpose of this study is to evaluate the association between the parenchymal subtype of NBS and posterior uveitis (PU). METHODS: We have retrospectively reviewed the clinical records of 295 patients with BS, who met the international classification criteria for BS, diagnosed at two major rheumatology clinics from 2010 to 2014. Patient demographics, ophthalmic examinations, clinical and radiologic patterns of neurological involvement were recorded. Manifestations of BS were classified as PU, NBS, vascular involvement, and arthritis. The association between clinical findings was analysed for statistical significance. RESULTS: Of the 295 patients, 100 had PU and 44 had NBS. 30 patients had parenchymal NBS and 14 had vascular NBS. Patients with PU were significantly more likely to have neurological involvement compared to those without PU (p<0.001; Odds Ratio: 3.924; 95% CI: 1.786-8.621). Rate of posterior uveitis was higher in patients with parenchymal NBS when compared to patients with vascular NBS, vascular BS or arthritis (63.3%, 21.4%, 22% and 4.2% respectively, p<0.001). CONCLUSIONS: Our findings suggest a clinically and statistically significant association between posterior uveitis and parenchymal type of neurologic involvement in BS. The development of posterior uveitis in a patient with previously diagnosed BS should be recognized as a "warning sign" for predisposition to neurologic involvement. These patients should be informed about the possible signs and symptoms of neurological involvement, which can cause very rapid and irreversible damage unless recognized and treated immediately.
Asunto(s)
Síndrome de Behçet/complicaciones , Enfermedades del Sistema Nervioso/etiología , Uveítis Posterior/etiología , Adulto , Síndrome de Behçet/diagnóstico , Síndrome de Behçet/tratamiento farmacológico , Distribución de Chi-Cuadrado , Progresión de la Enfermedad , Femenino , Humanos , Inmunosupresores/uso terapéutico , Masculino , Registros Médicos , Persona de Mediana Edad , Enfermedades del Sistema Nervioso/diagnóstico , Oportunidad Relativa , Pronóstico , Estudios Retrospectivos , Factores de Riesgo , Uveítis Posterior/diagnósticoRESUMEN
Hypoxic ischemic damage of the corpus callosum after cardiac arrest is a rare condition. Lesions of the splenium of the corpus callosum after hypoxia are bilateral and lead to poor prognosis. Herein, we present a case with good prognosis after cardiac arrest with bilateral lesions of the splenium of corpus callosum.